Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The company is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
